Zhu B, Sevick-Muraca E M
Center for Molecular Imaging, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, Houston, TX, USA.
Br J Radiol. 2015 Jan;88(1045):20140547. doi: 10.1259/bjr.20140547.
Near-infrared fluorescence (NIRF) molecular imaging holds great promise as a new "point-of-care" medical imaging modality that can potentially provide the sensitivity of nuclear medicine techniques, but without the radioactivity that can otherwise place limitations of usage. Recently, NIRF imaging devices of a variety of designs have emerged in the market and in investigational clinical studies using indocyanine green (ICG) as a non-targeting NIRF contrast agent to demark the blood and lymphatic vasculatures both non-invasively and intraoperatively. Approved in the USA since 1956 for intravenous administration, ICG has been more recently used off label in intradermal or subcutaneous administrations for fluorescence imaging of the lymphatic vasculature and lymph nodes. Herein, we summarize the devices of a variety of designs, summarize their performance in lymphatic imaging in a tabular format and comment on necessary efforts to develop standards for device performance to compare and use these emerging devices in future, NIRF molecular imaging studies.
近红外荧光(NIRF)分子成像作为一种新的“床旁”医学成像模式具有巨大潜力,它有可能提供核医学技术的灵敏度,但不存在可能限制其使用的放射性。最近,市场上出现了各种设计的NIRF成像设备,并且在研究性临床研究中使用吲哚菁绿(ICG)作为非靶向NIRF造影剂,以非侵入性和术中方式标记血液和淋巴管系统。自1956年在美国获批静脉给药以来,ICG最近已被用于非标签的皮内或皮下给药,用于淋巴管系统和淋巴结的荧光成像。在此,我们总结了各种设计的设备,以表格形式总结它们在淋巴成像中的性能,并评论为制定设备性能标准所必需的努力,以便在未来的NIRF分子成像研究中比较和使用这些新兴设备。